Toxicity of free p-cresol: A prospective and cross-sectional analysis

Clinical Chemistry

Volumn 49, Issue 3, 2003, Pages 470-478

  De Smet, Rita ^a   Van Kaer, Jacqueline ^a   Van Vlem, Bruno ^a   De Cubber, Antoine ^a   Brunet, Philippe ^b   Lameire, Norbert ^a   Vanholder, Raymond ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PARA CRESOL; SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CHEMOLUMINESCENCE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HOSPITALIZATION; HUMAN; HYPOALBUMINEMIA; INFECTION; LEUKOCYTE; MALE; PREVALENCE; PROSPECTIVE STUDY;

BLOOD PROTEINS; CHEMILUMINESCENT MEASUREMENTS; CRESOLS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LEUKOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RENAL DIALYSIS;

EID: 0037371201     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/49.3.470     Document Type: Article

References (50)

1. Vanholder R, de Smet R, Lameire N. Protein-bound uremic solutes: the forgotten toxins. Kidney Int Suppl 2000;78:S266-70.
2. Barre J, Didey F, Delion F, Tillement JP. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit 1988;10:133-43.
3. Burt M, Anderson DC, Kloss J, Apple FS. Evidence-based implementation of free phenytoin therapeutic drug monitoring. Clin Chem 2000;46:1132-5.
4. Lindow J, Wijdicks EF. Phenytoin toxicity associated with hypoalbuminemia in critically ill patients. Chest 1994;105:602-4.
5. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-7.
6. De Smet R, Vogeleere P, Van Kaer J, Lameire N, Vanholder R. Study by means of high-performance liquid chromatography of solutes that decrease theophylline/protein binding in the serum of uremic patients. J Chromatogr A 1999;847:141-53.
7. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, Santos BD, Dominguez-Gil A. Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. J Clin Pharm Ther 1993;18:191-7.
8. Kaysen GA. Inflammation nutritional state and outcome in end stage renal disease. Miner Electrolyte Metab 1999;25:242-50.
9. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, Hoste E, et al. Mechanisms of uremic ihhibition Of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995;47:510-7.
10. De Smet R, Glorieux G, Hsu C, Vanholder R. p-Cresol and uric acid: two old uremic toxins revisited. Kidney Int Suppl 1997;62:S8-11.
11. Vanholder R, De Smet R, Lesaffer G. p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity [Editorial]. Nephrol Dial Transplant 1999;14:2813-5.
12. De Smet R, Van Kaer J, Liebich H, Lesaffer G, Verstraete A, Dhondt A, et al. Heparin-induced release of protein-bound solutes during hemodialysis is an in Vitro artifact. Clin Chem 2001;47:901-9.
13. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney Int 1985;28:526-34.
14. De Smet R, David F, Sandra P, Van Kaer J, Lesaffer G, Dhondt A, et al. A sensitive HPLC method for the quantification of free and total p-cresol in patients with chronic renal failure. Clin Chim Acta 1998;278:1-21.
15. Grisham MB, Engerson TD, McCord JM, Jones HP. A comparative study of neutrophil purification and function. J Immunol Methods 1985;82:315-20.
16. Ritchey EE, Wallin JD, Shah SV. Chemiluminescence and superoxide anion production by leukocytes from chronic hemodialysis patients. Kidney Int 1981;19:349-58.
17. Walser M, Hill SB. Free and protein-bound tryptophan in serum of untreated patients with chronic renal failure. Kidney Int 1993;44:1366-71.
18. Grémy F, Salmon D: Bases statistiques pour la recherche médicale et biologique. In: Paris: Dunod, 1969:130.
19. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-23.
20. Dasgupta A, Jacques M. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera: Role of uremic compounds. Am J Clin Pathol 1994;101:349-53.
21. Cohen G, Haag-Weber M, Horl WH. Immune dysfunction in uremia. Kidney Int suppl 1997;62:S79-82.
22. Caballero-Quintero A, Pineyro-Lopez A, Waksman N. In vitro binding studies of the peroxisomicine A1-BSA and -HSA interactions. Int J Pharm 2001;229:23-8.
23. Lowrle EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990;15:458-82.
24. Johnson WJ, Hagge WW, wagoner RD, Dinapoli RP, Rosevear JW. Effects of urea loading in patients with far-advanced renal failure. Mayo Clin Proc 1972;47:21-9.
25. Langman LJ, LeGatt DF, Yatscoff RW. Blood distribution of mycophenolic acid. Ther Drug Monit 1994;16:602-7.
26. Zini R, Morin D, Salvadori C, Tillement JP. Tianeptine binding to human plasma proteins and plasma from patients with hepatic cirrhosis or renal failure. Br J Clin Pharmacol 1990;29:9-18.
27. Mabuchi H, Nakahashi H. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum. Ther Drug Monit 1988;10:261-4.
28. Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. Am J Kidney Dis 1994;24:1002-9.
29. Hakim RM, Levin N. Malnutrition in hemodialysis patients. Am J Kidney Dis 1993;21:125-37.
30. Tayeb JS, Provenzano R, El Ghoroury M, Bellovich K, Khairullah Q, Pieper D, et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis 2000;35:606-10.
31. Yeun JY, Levine RA, Mantadilok V, Kaysen GA. C-Reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kidney Dis 2000;35:469-76.
32. Suliman ME, Qureshi AR, Barany P, Stenvinkei P, Filho JC, Anderstam B, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 2000;57:1727-35.
33. Miyazaki T, Ise M, Hirata M, Endo K, Ito Y, Seo H, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-β 1 and progression of renal failure. Kidney Int Suppl 1997;63: S211-4.
34. Sakai T, Yamasaki K, Sako T, Kragh-Hansen U, Suenaga A, Otagiri M. Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin. Pharm Res 2001;18:520-4.
35. Depner TA. Suppression of tubular anion transport by an inhibitor of serum protein binding in uremia. Kidney Int 1981;20:511-8.
36. Greco AV, Mingrone G, Favuzzi A, Bertuzzi A, Gandolfi A, De Smet R, et al. Subclinical hepatic encephalopathy: role of tryptophan binding to albumin and the competition with indole-3-acetic acid. J Investig Med 2000;48:274-80.
37. Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron 1990;56:241-5.
38. Tsutsumi Y, Maruyama T, Takadate A, Shimada H, Otagiri M. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid. Nephron 2000;85:60-4.
39. Wardle EN, Williams R. Polymorph leucocyte function in uraemia and jaundice. Acta Haematol 1980;64:157-64.
40. Niwa T, Katsuzaki T, Momoi T, Miyazaki T, Ogawa H, Saito A, et al. Modification of β2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Kidney Int 1996;49:861-7.
41. Witko-Sarsat V, Friedlander M, Nguyen KT, capeillere-Blandin C, Nguyen AT, Canteloup S, et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998;161:2524-32.
42. Miyata T, Oda O, Inagi R, Iida Y, Araki N, Yamada N, et al. β2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 1993;92:1243-52.
43. Johansen KL, Mulligan K, Tai V, Schambelan M. Leptin, body composition, and indices of malnutrition in patients on dialysis. J Am Soc Nephrol 1998;9:1080-4.
44. Young GA, Woodrow G, Kendall S, Oldroyd B, Turney JH, Brownjohn AM, et al. Increased plasma leptin/fat ratio in patients with chronic renal failure: a cause of malnutrition? Nephrol Dial Transplant 1997;12:2318-23.
45. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995;114:93-103.
46. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease [see comments]. N Engl J Med 1991;324:1149-55.
47. Niwa T. Organic acids and the uremic syndrome: protein metabolite hypothesis in the progression of chronic renal failure. Semin Nephrol 1996;16:167-82.
48. Dzurik R, Spustova V, Gerykova M. Pathogenesis and consequences of the alteration of glucose metabolism in renal insufficiency. Adv Exp Med Biol 1987;223:105-9.
49. 2+-ATPase in end-stage renal failure. Kidney Int Suppl 2001;78:S84-8.
50. Schoots AC, De Vries PM, Thiemann R, Hazejager WA, Visser SL, Oe PL. Biochemical and neurophysiological parameters in hemodialyzed patients with chronic renal failure. Clin Chim Acta 1989;185:91-107.